Dapsone: use in immunobullous disorders
DOI:
https://doi.org/10.66344/jpad.v15i2.637Keywords:
Dapsone, toxicity, dermatitis herpetiformis, linear IgA disease, bullous pemphigoid, cicatricial pemphigoid, bullous SLE, epidermolysis bullosa acquisita, pemphigus.Abstract
Dapsone and other sulfonamides have been used successfully in the treatment of patients with
a variety of blistering skin diseases. The patients most likely to respond to dapsone therapy
have predominantly neutrophilic infiltrate in their skin e.g. dermatitis herpetiformis and linear
IgA disease. The precise mechanism of action of dapsone is unknown. In vitro studies have
shown that dapsone can interfere with the production of and response to neutrophilic
chemotactants and that it may impair the neutrophils' ability to localize to sites of
inflammation and produce toxic oxygen intermediates. The safe use of dapsone requires an
understanding of the pharmacology and adverse effects of the drug. Hemolytic anemia and
methemoglobinemia are two of the dose-related adverse effects. Agranulocytosis, motor
neuropathy, and dapsone hypersensitivity syndrome are some of the severe idiosyncratic
effects that can occur in patients treated with dapsone. Careful patient selection and close
monitoring of patients during therapy with dapsone are critical elements in the safe and
effective use of dapsone for patients with blistering skin diseases.
References
1. Costello MJ. Dermatitis herpetiformis treated with sulfapyridine. Arch Dermatol Syphilol 1940; 41:134-40.
2. Swartz JH, Lever WF. Dermatitis herpetiformis: Immunology and therapeutic considerations. Arch Dermatol Syphilol 1943; 47: 680-5.
3. Uetrecht JP. Dapsone and sulfapyridine. Clin Dermatol 1989; 7: 111-20.
4. Mancey-Jones B. The mode of action of dapsone in leprosy and other disorders. In: Ryan TJ, McDougall AC, eds. Essay on Leprosy. Oxford: Alden Press; 1988.
p. 141-72.
5. Swain AF, Ahmad RA, Rogers HJ et al. Pharmacokinetic observation on dapsone in dermatitis herpetiformis. Br J Dermatol 1983; 108: 91-8.
6. Sanders SW, Zone H. The relationship between dapsone dose, serum concentration and disease severity in dermatitis herpetiformis. Arzneimittelforschung 1986; 36: 146-9.
7. Sanders SW, Zone H, Foltz RL et al. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med 1982; 96: 465-6.
8. Maurus IN. Hansen's disease in pregnancy. Obstet Gynecol 1978: 52:
22-5.
9. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299-315.
10. Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995: 40: 531-8.
11. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia. Drug Metab Rev 1995: 27: 107-
24.
12. Cucinell SA, Israili ZH, Dayton PG. Microsomal N-oxidation of dapsone as a cause of methemoglobin formation in human red cells. Am J Trop Med Hyg 1972; 21: 322-31.
13. May DG, Arns PA, Richards WO et al. The disposition of dapsone in cirrhosis. Clin Pharmacol Ther 1992; 51: 689-
700.
14. Schmidt E, Reimer S, Kruse N et al. The IL-8 release from human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 2001; 124: 157-62.
15. Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995; 8:
196-202.
16. Maloff BL, Fox D, Bruin E, Di MT. Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels. Eur J Pharmacol 1988; 158: 85-89.
17. Stendahl O, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 1977; 62: 214-20.
18. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol 1978; 70: 51-5.
19. Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992; 44: 553-63.
20. Fry L. The treatment of dermatitis herpetiformis. Clin Exp Dermatol 1982; 7: 633-42.
21. Katz SI. Treatment: drugs and diet. Dermatitis herpetiformis: the skin and the gut. Ann Intern Med 1980; 93: 857-
74.
22. Chorzelski TP, Jablonska S. IgA linear dermatosis of childhood (chronic bullous disease of childhood). Br J Dermatol 1979; 101: 535-42.
23. Wojnarowska F, Marsden RA, Bhogal B, Black MM. Chronic bullous disease of childhood, childhood cicatricial pemphigoid and linear IgA disease of adults; A comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol 1988; 19: 792-805.
24. Hall RP, Lawley TJ, Smith HR, Katz SI. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165-70.
25. Bystryn IC. Adjuvant therapy of pemphigus. Arch Dermatol 1984; 120:
941-51.
26. Bystryn IC. Therapy of pemphigus.
Semin Dermatol 1988; 7: 186-94.
27. Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978; 156: 120-3.
28. Honeyman IF, Honeyman AR, De la Parra MA et al. Polymorphic pemphigoid. Arch Dermatol 1979; 115:
423-7.
29. Jeffes EWB III, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol 1989; 14:
132-6.
30. Basset N, Guillot B, Michel B et al. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987: 123: 783-5.
31. Yasuda H, Kobayashi H, Hashimoto T et al. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-l and clinical review. Br J Dermatol 2000; 143: 144-8.
32. Ongenae KC, Temmerman IL, Vermander F, Naeyaert JM. Intercellular IgA dermatosis. Eur J Dermatol 1999; 9: 85-94.
33. Hjelm M, De Verdier CH. Biochemical effects of aromatic amines-I Methaemoglobinaemia, haemolysis and Heinz body formation induced by 4,4'-diaminodiphenylsulphone. Biochem Pharmacol 1965; 14: 1119-28.
34. Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995; 26: 1461-7.
35. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993; 129: 507-13.
36. Prussick R, Ali MA, Rosenthal D, Guyatt G. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992; 128: 210-3.
37. Coleman MD, Rhodes LE, Scott AK et al. The use of cimetidine to reduce dapsone-dependent methaemoglobin aemia in dermatitis herpetiformis patients. Br J Clin Pharmacol 1992; 34: 244-9.
38. Rhodes LE, Tingle MD, Park BK et al. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br J Dermatol 1995; 132: 257-62.
39. Hornsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol
1990; 126: 919-22.
40. Cockburn EM, Wood SM, Waller PC, Bleehen SS. Dapsone induced agranulocytosis: spontaneous reporting data. Br J Dermatol 1993; 128: 702- 3.
41. Coleman MD. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001; 162: 53-60.
42. Saqueton AC, Lorincz AL, Vick NA, Harner RD. Dapsone and peripheral motor neuropathy. Arch Dermatol 1969; 100: 214-7.
43. Waldinger TP, Siegle RJ, Weber W, Voorhees IJ. Dapsone induced peripheral neuropathy. Case report and review. Arch Dermatol l984; 120: 356-
9.
44. Koller WC, Gehlmann LK, Malkinson FD, Davis FA. Dapsone-induced peripheral neuropathy. Arch Neurol 1977: 34: 644-6.
45. Daneshmend TK. The neurotoxicity of dapsone. Adv Drug React Ac Pois Rev 1984; 3: 43-58.
46. Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy-an axonal disease. Neurology 1976; 26: 5-6.
47. Homeida M, Babikr A, Daneshmend TK. Dapsone-induced optic atrophy and motor neuropathy. BMJ 1980; 281:
1180.
48. Daneshmend TK. Idiosyncratic dapsone induced manic depression. BMJ 1989; 299: 324.
49. Fine JD, Katz SI, Donahue MJ, Hendricks M. Psychiatric reaction to dapsone and sulfapyridine. J Am Acad Dermatol 1983; 9: 274-5.
50. Gawkrodger D. Manic depression induced by dapsone in patient with dermatitis herpetiformis. Br Med J 1989; 299: 860.
51. Millikan LE, Harrell ER. Drug reactions to sulfones. Arch Dermatol l970; 102: 220-4.
52. Johnson DA, Cattau EL Jr, Kuritsky IN. Liver involvement in the sulfone syndrome. Arch Intern Med 1986; 146:
875-7.
53 Kingham JGC, Swain P, Swarbrick ET et al. Dapsone and severe hypoalbuminaemia. Lancet 1979; 2:
662-4.
54 Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol l996; 35: 346-9.
55 Frey HM, Gershon M, Borkowsky W, Bullock WE. Fatal reaction to dapsone during treatment of leprosy. Ann Intern Med 1981; 94: 777-9.
56 Lawrence WA, Olsen HW, Nickles DJ. Dapsone hepatitis. Arch Intern Med 1987; 147: 175.
57 Gupta AK, Eggo MC, Uetrecht J. Pharmacodynamics and drug action. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56-67.
58 Kumar RH, Kumar MV, Thappa DM. Dapsone syndrome a five year retrospective analysis. Indian J Lepr 1998; 70: 271-6.
59 Peters JH. Carcinogenic activity of dapsone. Int J Lepr 1976; 44: 383-4.
60 Collier PM, Kelly SE, Wojnarowska F. Linear IgA disease and pregnancy. J Am Acad Dermatol 1994; 30: 407-11.
61 Kahn G. Dapsone is safe during pregnancy. J Am Acad Dermatol l985; 13: 7-9
62 Motulsky AG, Yoshida A, Stametoyannopoulos G. Variants of glucose-6-phosphate dehydrogenase. Ann N Y Acad Sci 1971; 179: 636-43.
63 Todd P, Samaratunga JR, Pembroke A. Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy. Clin Exp Dermatol 1994; 19: 217-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Shagufta Shafi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
